MAX EdGE™ PROGRAM
Education | Growth | Expertise
brought to you by AbbVie

BOTOX® onabotulinumtoxinA injection

Chronic Migraine

The MAXEdGE™ Programmatic Training Guide

for Advanced Practice Providers (APPs)

With the **MAXEdGE**™ Program from AbbVie, you can seek the extra *EdGE* in support with comprehensive resources and education tailored to help you:

- **Learn from other injectors**
- **Expand your Chronic Migraine education and BOTOX® treatment considerations**
- **Support the patients you treat with the latest educational tools and resources to help manage a debilitating disease**
- **Enhance your expertise as a BOTOX® injector**

INDICATION
Chronic Migraine
BOTOX® (onabotulinumtoxinA) for injection is indicated for the prophylaxis of headaches in adult patients with chronic migraine (≥15 days per month with headache lasting 4 hours a day or longer).

Limitations of Use
Safety and effectiveness have not been established for the prophylaxis of episodic migraine (14 headache days or fewer per month) in 7 placebo-controlled studies.

IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING

WARNING: DISTANT SPREAD OF TOXIN EFFECT
Postmarketing reports indicate that the effects of BOTOX and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening, and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses and approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and spasticity and at lower doses.

Please see additional Important Safety Information about BOTOX® on following pages.

Please see full Prescribing Information, including Boxed Warning and Medication Guide, at https://www.rxabbvie.com/pdf/botox_pi.pdf

BOTOX® onabotulinumtoxinA injection

MAXEdGE™—a Path to Becoming a BOTOX® Injector for Chronic Migraine

The MAXEdGE™ Program is a comprehensive BOTOX® injector training program developed specifically for APPs by your peers

When you're ready for the extra *EdGE* to advance your knowledge in Chronic Migraine care, find the latest educational offerings with the **MAXEdGE™** Program that will take you to the next level every step of the way.

Education

Engage with expert BOTOX® injectors to learn more through:

- 1:1 connections
- Peer-to-peer training
- Comprehensive step-wise training continuum

Growth

Advance injector knowledge with:

- Ongoing learning modules
- Hands-on training and education
- Patient educational tools and resources

Expertise

Build confidence as a BOTOX® injector with:

- Advanced education and programming
- A community effort to advance patient care
- Exchange of best practices

No matter where you are in your journey, you can access our latest support and training resources to help you provide the care your appropriate Chronic Migraine patients deserve.

Scan to learn how you can enroll in the MAXEdGE™ Program and take the next step in advancing your BOTOX® for Chronic Migraine expertise.

IMPORTANT SAFETY INFORMATION (continued)
CONTRAINDICATIONS
BOTOX is contraindicated in the presence of infection at the proposed injection site(s) and in patients who are hypersensitive to any botulinum toxin product or to any of the components in the formulation.

WARNINGS AND PRECAUTIONS
Spread of Toxin Effect
See *Boxed Warning*.

No definitive serious adverse event reports of distant spread of toxin effect associated with BOTOX for chronic migraine at the labeled dose have been reported.

Please see additional Important Safety Information throughout.

Getting Started as a BOTOX® Injector

A Training Continuum That Aligns With Your Experience

The **MAXEdGE**™ Programmatic Training Program for BOTOX® is led by a team of individuals:

- Your Account Specialist will provide clinical training and guide you along the BOTOX® training continuum
- Your Reimbursement Business Advisor (RBA) will provide education on the operational aspects of BOTOX®, such as patient access, payer coverage criteria, prior authorization, and reimbursement processes, including APP-relevant information
- Throughout your learning journey, you will be paired with a peer expert, which will be based on your individual needs and include a variety of touch points along a step-wise approach

The entire hands-on onboarding process may take 1 to 3 months, depending on your specific area and needs.

The MAXEdGE™ training journey can accelerate the BOTOX® learning process with:



- Peer-to-peer disease state education
- Account Specialist in-service training
- On-demand expert-led presentations
- Customized peer-to-peer video conferences
- Preceptorship and proctorship observational training
- BOTOX® injection day prep
- Treatment and post-injection day support
- Regular touch points with a Reimbursement Business Advisor for staff training and in-office BOTOX® practice management education

Following training, your Account Specialist will continue case observations to help address any follow-up questions and recommend additional programs if needed.

IMPORTANT SAFETY INFORMATION (continued)
WARNINGS AND PRECAUTIONS (continued)
Lack of Interchangeability Between Botulinum Toxin Products
The potency Units of BOTOX are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, Units of biological activity of BOTOX cannot be compared to nor converted into Units of any other botulinum toxin products assessed with any other specific assay method.

Serious Adverse Reactions With Unapproved Use
Serious adverse reactions, including excessive weakness, dysphagia, and aspiration pneumonia, with some adverse reactions associated with fatal outcomes, have been reported in patients who received BOTOX injections for unapproved uses. In these cases, the adverse reactions were not necessarily related to distant spread of toxin, but may have resulted from the administration of BOTOX to the site of injection and/or adjacent structures. In several of the cases, patients had preexisting dysphagia or other significant disabilities. There is insufficient information to identify factors associated with an increased risk for adverse reactions associated with the unapproved uses of BOTOX. The safety and effectiveness of BOTOX for unapproved uses have not been established.

Hypersensitivity Reactions
Serious and/or immediate hypersensitivity reactions have been reported. These reactions include anaphylaxis, serum sickness, urticaria, soft-tissue edema, and dyspnea. If such a reaction occurs, further injection of BOTOX should be discontinued and appropriate medical therapy immediately instituted. One fatal case of anaphylaxis has been reported in which lidocaine was used as the diluent, and consequently, the causal agent cannot be reliably determined.

Please see additional Important Safety Information throughout.

Advancing Your Education With an Extensive Catalog of BOTOX® Training Programs

Your participation in the **MAXEdGE**™ Program offers various opportunities to help grow and develop your expertise about BOTOX® for Chronic Migraine. Get access to cutting-*EdGE* resources to help manage Chronic Migraine with local and regional programming, expert peer connections, and a community working together to support Chronic Migraine patient care.

MAXEdGE™ Program Training Initiatives for Chronic Migraine

Disease State Education

An in-person or virtual presentation designed to provide foundational education about disease state, pathophysiology, and the treatment landscape.

Masterclass On-Demand Series

Virtual presentations on select topics, including:

I. **Making BOTOX® the Next Step in Chronic Migraine.** Understanding the Chronic Migraine disease state and burden, patient ID/diagnosing Chronic Migraine, and patient dialogue

II. **Anatomy to Injection.** Focus on the PREEMPT* injection protocol and injection insights and considerations

III. **Facilitating Patient Access.** Staff education and the team approach to the patient journey in practice.

Preceptorship

In-clinic observational training at expert clinical faculty's practice (trainee visits) with live patient treatment using the PREEMPT* injection protocol. Typically, a half-day program with a minimum of 4 to 6 confirmed patients.

Proctorship

Typically, a half day in-clinic program at trainee's practice (faculty visits) with 4 to 6 confirmed patients, including live patient observational training and expert injection guidance.

Expert-On-Demand

Customized, 1:1 video conference with expert clinical faculty that includes a tailored presentation and open Q&A based on trainee's educational needs.

Case Observation

Silent observation from Account Specialists on procedure and clinic days to help identify appropriate resources to elevate injector competence and confidence.

Earn a **certificate of completion** following each program to affirm your skills as a BOTOX® injector for Chronic Migraine

*__PREEMPT__ = **P**hase 3 **RE**search **E**valuating **M**igraine **P**rophylaxis **T**herapy.

IMPORTANT SAFETY INFORMATION (continued)
WARNINGS AND PRECAUTIONS (continued)
Increased Risk of Clinically Significant Effects With Preexisting Neuromuscular Disorders
Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis (ALS), or neuromuscular junction disorders (eg, myasthenia gravis or Lambert-Eaton syndrome) should be monitored when given botulinum toxin. Patients with known or unrecognized neuromuscular disorders or neuromuscular junction disorders may be at increased risk of clinically significant effects, including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia, and respiratory compromise from therapeutic doses of BOTOX (see *Warnings and Precautions*).

Dysphagia and Breathing Difficulties
Treatment with BOTOX and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with preexisting swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or oropharyngeal muscles that control swallowing or breathing (see *Boxed Warning*).

IMPORTANT SAFETY INFORMATION (continued)
WARNINGS AND PRECAUTIONS (continued)
Human Albumin and Transmission of Viral Diseases
This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would also be considered extremely remote. No cases of transmission of viral diseases, CJD, or vCJD have ever been identified for licensed albumin or albumin contained in other licensed products.

ADVERSE REACTIONS
Adverse reactions to BOTOX for injection are discussed in greater detail in the following sections: *Boxed Warning*, *Contraindications*, and *Warnings and Precautions*.

Please see additional Important Safety Information throughout.

MAX EdGE™

BOTOX® onabotulinumtoxinA injection

See What You Can Discover by **Joining the MAXEdGE™ Program**

- A community of peers working together to identify and treat Chronic Migraine patients
- Training and education programming
- Dedicated AbbVie Account Specialists
- Office tools and resources
- Dedicated Reimbursement Business Advisor

Talk to your Account Specialist about additional training opportunities in the MAXEdGE™ Program

Scan to hear an expert BOTOX® injector share their story about when it was Crystal Clear they could do more to help Chronic Migraine patients in our Crystal Clear Moments Series.

IMPORTANT SAFETY INFORMATION (continued)
ADVERSE REACTIONS (continued)
Chronic Migraine
The most frequently reported adverse reactions following injection of BOTOX for chronic migraine vs placebo include, respectively, neck pain (9% vs 3%); headache (5% vs 3%); eyelid ptosis (4% vs <1%); migraine (4% vs 3%); muscular weakness (4% vs <1%); musculoskeletal stiffness (4% vs 1%); bronchitis (3% vs 2%); injection-site pain (3% vs 2%); musculoskeletal pain (3% vs 1%); myalgia (3% vs 1%); facial paresis (2% vs 0%); hypertension (2% vs 1%); and muscle spasms (2% vs 1%).

Postmarketing Experience
Adverse reactions that have been identified during postapproval use of BOTOX are discussed in greater detail in *Postmarketing Experience* (Section 6.3 of the Prescribing Information).

There have been spontaneous reports of death, sometimes associated with dysphagia, pneumonia, and/or other significant debility or anaphylaxis, after treatment with botulinum toxin. There have also been reports of adverse events involving the cardiovascular system, including arrhythmia and myocardial infarction, some with fatal outcomes. Some of these patients had risk factors, including cardiovascular disease. The exact relationship of these events to the botulinum toxin injection has not been established.

DRUG INTERACTIONS
Co-administration of BOTOX and other agents interfering with neuromuscular transmission (eg, aminoglycosides, curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated. Use of anticholinergic drugs after administration of BOTOX may potentiate systemic anticholinergic effects. The effect of administering different botulinum neurotoxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin. Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of BOTOX.

Please see additional Important Safety Information on previous pages.

Please see full Prescribing Information, including Boxed Warning and Medication Guide, at https://www.rxabbvie.com/pdf/botox_pi.pdf

abbvie

US-BCM-250272 08/2025 031701